BIOMOTCPharmaceutical PreparationsFiscal year ends December 31

BIOMOLECULAR LIFE HOLDINGS, INC.

Financials through Q3 FY2015, quarter ended Sep 30, 2015Last filing: 10-Q on Nov 19, 2015

$0.79−0.02 (-2.47%)

Close on Oct 19, 2026

Market cap: $67.51M
P/E (TTM): –
Dividend yield: –

BIOMOLECULAR LIFE HOLDINGS, INC. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	0	0
Research & Development	0.87	0.81
General & Administrative	0.91	1.35
Total Costs & Expenses	4.14	3.91
Operating Income	-4.14	-3.91
Interest Expense	2.76	1.08
Other Non-Operating Income	-2.08	-3.57
Asset Impairment Charges	0	0
Income Tax Expense	0	0
Net Income incl. Noncontrolling Interests	-6.22	-7.48
Minority Interest in Earnings	-0.03	-0.06
Net Income	-6.19	-7.42
EPS (Basic)(per share)	-0.22	-0.91
EPS (Diluted)(per share)	-0.22	-0.91
Shares Outstanding (Basic, Weighted)(shares)	28	8.19
Shares Outstanding (Diluted, Weighted)(shares)	28	8.19
EBITDA	-4.14	-3.91

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2015

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2014: 137.9%

Financial strength

Current ratio: 0.01
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –